Stocks and Investing Stocks and Investing
Mon, April 22, 2013

Andrew Peters Maintained (BIIB) at Strong Buy with Increased Target to $240 on, Apr 22nd, 2013


Published on 2024-10-25 02:29:44 -
  Print publication without navigation


Andrew Peters of Deutsche Bank, Maintained "Biogen Inc." (BIIB) at Strong Buy with Increased Target from $170 to $240 on, Apr 22nd, 2013.

Andrew has made no other calls on BIIB in the last 4 months.



There are 6 other peers that have a rating on BIIB. Out of the 6 peers that are also analyzing BIIB, 2 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013


These are the ratings of the 4 analyists that currently disagree with Andrew


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $215 on, Tuesday, April 9th, 2013
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $225 on, Thursday, April 4th, 2013
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $206 on, Monday, April 1st, 2013
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $188 on, Monday, March 25th, 2013